538 related articles for article (PubMed ID: 23731598)
1. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
O'Connor AB; Noyes K; Holloway RG
J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
[TBL] [Abstract][Full Text] [Related]
6. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
Johnson P; Becker L; Halpern R; Sweeney M
Clin Drug Investig; 2013 Jan; 33(1):35-44. PubMed ID: 23179473
[TBL] [Abstract][Full Text] [Related]
8. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
O'Connor AB; Noyes K; Holloway RG
Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
11. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine.
Bellows BK; Nelson RE; Oderda GM; LaFleur J
Pain; 2016 Jan; 157(1):203-213. PubMed ID: 26397932
[TBL] [Abstract][Full Text] [Related]
12. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of pharmacoeconomic studies for pregabalin.
Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
[TBL] [Abstract][Full Text] [Related]
14. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin: new drug. Very similar to gabapentin.
Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
[TBL] [Abstract][Full Text] [Related]
18. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
Ogawa S; Satoh J; Arakawa A; Yoshiyama T; Suzuki M
Drug Saf; 2012 Oct; 35(10):793-806. PubMed ID: 22967187
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia.
Vinik A; Emir B; Parsons B; Cheung R
Pain Med; 2014 Apr; 15(4):661-70. PubMed ID: 24330406
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Dakin H; Nuijten M; Liedgens H; Nautrup BP
Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
